Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2013 | short review

Upper gastrointestinal cancer: POST ASCO 2013

verfasst von: Ewald Wöll, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Overall survival of patients suffering from upper gastrointestinal (GI) cancer is still poor. Most of the patients are diagnosed in advanced stages. But even in patients with operable disease, the recurrence rates, especially of gastric and pancreatic neoplasias, are still very high. Much effort has therefore been put in the development of palliative and curative therapeutic concepts. The aim of this article is to summarize the most important publications presented at American Society of Clinical Oncology (ASCO) 2013 concerning gastric and pancreatic cancer with the main focus on relevance for clinical practice.
Vorheriger Artikel Molecular therapies of colorectal cancer: where will we go from here?
Literatur
1.
Fukutomi A, Uesaka K, Boku N, et al. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol. 2013;31 (Suppl; abstr 4008).
2.
Von Hoff DD, Ervin ThJ, Arena FP, et al. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol. 2013;31 (Suppl; abstr 4005).
3.
Rivera F, Jiménez P, Alfonso PG, et al. NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—R0 resection, pCR, and toxicity analysis. J Clin Oncol. 2013;31 (Suppl; abstr 4098).
4.
Yoshida K, Tsuburaya A, Kobayashi M, et al. SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer. J Clin Oncol. 2013;31 (Suppl; abstr LBA4002).
5.
Hecht RJ, Bang Y-J, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC trial. J Clin Oncol. 2013;31 (Suppl; abstr LBA4001).
6.
Thuss-Patience PC, Kretzschmar A, Bichev D. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306–14.PubMedCrossRef
7.
Cook N, Marshall A, Blazeby JM, et al. Cougar-02: a randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. J Clin Oncol. 2013;31 (Suppl; abstr 4023).
8.
Fuchs CS, Tomasek J, Cho JY, et al. REGARD: a phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy. J Clin Oncol. 2012; 30 (Suppl 34; abstr LBA5).
Metadaten
Titel
Upper gastrointestinal cancer: POST ASCO 2013
verfasst von
Ewald Wöll, MD
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0105-9

Weitere Artikel der Ausgabe 3/2013

ASH 2012: “Helping hematologists conquer blood diseases worldwide”

  • editorial

Aggressive lymphoma at ASH 2012: new standards and new perspectives

  • short review

ASH 2012: allogeneic stem cell transplantation

  • short review

Radiofrequency ablation in gastrointestinal cancer: obstacles and goals

  • short review

ASH Annual Meeting 2012—Chronic Myeloid Leukemia Update

  • short review

ASH 2012 update chronic lymphocytic leukemia—the best is yet to come

  • short review